Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/19850678http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/19850678http://www.w3.org/2000/01/rdf-schema#comment"

Context

The deletion of exon 3 in the GH receptor (GHR) has been associated with a different biochemical picture and response to therapy in acromegaly.

Objective

The aim of the study was to determine whether or not the GHR genotype influences the efficacy of pegvisomant treatment.

Design and setting

A cross-sectional study was conducted in six Spanish university hospitals.

Patients

Forty-four acromegalic patients with active disease and resistance to somatostatin analogs participated in the study.

Results

The prevalence of the full-length GHR and the exon 3-deleted GHR homozygous and heterozygous genotypes was 41, 2, and 57%, respectively. There were no differences in IGF-I or GH pre-pegvisomant levels related to GHR genotype. The exon 3-deleted patients required approximately 20% lower doses of pegvisomant per kilogram of weight (28 +/- 11 compared to 22 +/-7 mg per kg of weight; P = 0.033) to normalize IGF-I. A stepwise multivariate linear regression analysis (R(2) = 0.27; P = 0.003) identified male gender (beta = -0.79; P = 0.03) and d3-GHR genotype (beta = -0.64; P = 0.007) as the only significant predictors of the dose of pegvisomant per kilogram of weight. In addition, d3-GHR carriers required fewer months for IGF-I normalization (P < 0.01). A stepwise multivariate linear regression analysis (R(2) = 0.40; P = 0.001) revealed that the only significant predictor of the time to IGF-I normalization was the dose of pegvisomant per kilogram of weight (beta = 0.451; P = 0.001).

Conclusions

The exon 3 deletion in the GHR predicts an improved response to pegvisomant therapy in acromegaly."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.org/dc/terms/identifier"doi:10.1210/jc.2009-1630"xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Bernabeu I."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Loidi L."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Quinteiro C."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Lucas T."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Casanueva F.F."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Marazuela M."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Halperin I."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Puig-Domingo M."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Luque-Ramirez M."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Alvarez-Escola C."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"Fernandez-Rodriguez E."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/author"de Miguel-Novoa P."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/date"2010"xsd:gYear
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/name"J Clin Endocrinol Metab"xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/pages"222-229"xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/title"The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly."xsd:string
http://purl.uniprot.org/citations/19850678http://purl.uniprot.org/core/volume"95"xsd:string
http://purl.uniprot.org/citations/19850678http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/19850678
http://purl.uniprot.org/citations/19850678http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/19850678
http://purl.uniprot.org/uniprot/#_A0A087X0H5-mappedCitation-19850678http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19850678
http://purl.uniprot.org/uniprot/#_A0A087X162-mappedCitation-19850678http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19850678
http://purl.uniprot.org/uniprot/#_A0A8A6U7T3-mappedCitation-19850678http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19850678
▶